We caution you therefore against relying on any of these forward-looking statements. Any return on investment may be limited to the value of our common stock. &# 183;We have a significant number of outstanding options. NAD+ is an essential coenzyme and a key regulator of cellular metabolism. NIAGEN® is safe for human consumption. We have been able to successfully conduct business virtually. Below is a list of some of the competitors for our ingredients segment. Below is a current list of certain competitors. Grace") is the Company's exclusive manufacturer for the supply of NR. These orders amount to approximately $25,000 or less. Our capital requirements will depend on many factors. These additional funds may not be available on favorable terms, or at all. There can be no assurance we will be successful in raising these additional funds. In addition, a product recall may require significant management attention. Due to COVID-19, there may be delays in shipments from our suppliers. In addition to being expensive, maintaining such a sales force is time-consuming. We may also need to contract with third parties in order to market our products. Actual results may differ from these estimates under different assumptions or conditions. As of December 31, 2020, cash and cash equivalents totaled approximately $16.7 million. 2)Excluded from the computation of loss per share as their impact is antidilutive. Net cash provided by (used in) investing activities. We make monthly payments on these leases. Accordingly, we express no such opinion. Subsequent Events for more details. The Company adopted this guidance on a prospective basis in 2020. Our trade receivables are derived from sales to our customers. We assess credit risk of our customers through quantitative and qualitative analysis. From this analysis, we establish credit limits and manage the risk exposure. The inventory on the balance sheet is recorded net of valuation allowances. Our normal operating cycle for reference standards is currently longer than one year. Maintenance and repairs are charged to operating expenses as they are incurred. Improvements and betterments, which extend the lives of the assets, are capitalized. For the expected term, the Company uses SEC Staff Accounting Bulletin No. The fair value hierarchy gives the highest priority to Level 1 inputs. This provision is effective for CFC tax years beginning after December 31, 2017. Related Party Transactions Sale of consumer products Net salesYear endedDec. The court denied Defendants' motion on February 4, 2019. The court set the hearing on the motion for May 3, 2021. ( Elysium moved for reconsideration on January 17, 2019. On March 12, 2020, Elysium Health answered the second amended complaint. Elysium filed its reply in support of its motion to dismiss on May 26, 2020. ChromaDex, Inc. filed a motion for reargument on December 29, 2020. Fact discovery closed on January 26, 2021. Responsive expert reports were served on March 9, 2021. No lawsuit has been filed to date. On February 1, 2021, Thorne filed a petition for IPR of the ‘807 Patent. 50Table of Contents PART III Item 10. 333-239144] and on Form S-8 [File No. The base salary may be increased from time to time. 6.2& Non-Competition During Employment. 7.2& Termination Without Cause or Resignation for Good Reason. 63K6EV&N:#?Z+JD(FL+Z![:,\\;D M=2K#/;@]U:U% \'GVB^$?&&EV=GHMYXX74-#L\\)&?[/,. MYZA&?_G\\]$-6/^$A^,G_ $$/"O\\ X([G_P"3*] UNU@76O#($8YU!P?_ 5KH_A7PEHEK
